ZA200602899B - 5,7-Diaminopyrazolo [4,3-d] Pyrimidlnes with PDE-5 Inhibiting Activity - Google Patents

5,7-Diaminopyrazolo [4,3-d] Pyrimidlnes with PDE-5 Inhibiting Activity Download PDF

Info

Publication number: ZA200602899B
Authority: ZA; South Africa
Prior art keywords: compound according; nitrogen; sulphur; oxygen; optionally substituted
Prior art date: 2003-11-24

Application number

ZA200602899A

Other languages

English (en)

Inventor

Bell Andrew Simon

Dack Kevin Neil

Marsh Ian Roger

Palmer Michael John

Brown David Graham

Fox David Nathan Abraham

Morrell Andrew Ian

Winslow Carol Ann

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-24

Filing date

2006-04-10

Publication date

2007-07-25

2006-04-10 Application filed by Pfizer filed Critical Pfizer

2007-07-25 Publication of ZA200602899B publication Critical patent/ZA200602899B/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Child & Adolescent Psychology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

ZA200602899A 2003-11-24 2006-04-10 5,7-Diaminopyrazolo [4,3-d] Pyrimidlnes with PDE-5 Inhibiting Activity ZA200602899B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0327319.0A GB0327319D0 (en)	2003-11-24	2003-11-24	Novel pharmaceuticals

Publications (1)

Publication Number	Publication Date
ZA200602899B true ZA200602899B (en)	2007-07-25

Family

ID=29764364

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200602899A ZA200602899B (en)	2003-11-24	2006-04-10	5,7-Diaminopyrazolo [4,3-d] Pyrimidlnes with PDE-5 Inhibiting Activity

Country Status (44)

Country	Link
EP (1)	EP1689751B1 (xx)
JP (1)	JP4056015B2 (xx)
KR (2)	KR100848216B1 (xx)
CN (4)	CN101362764B (xx)
AP (1)	AP2227A (xx)
AR (1)	AR046711A1 (xx)
AT (1)	ATE485297T1 (xx)
AU (1)	AU2004290643B2 (xx)
BR (1)	BRPI0416869A (xx)
CA (1)	CA2546987C (xx)
CR (1)	CR8416A (xx)
CY (1)	CY1110933T1 (xx)
DE (1)	DE602004029705D1 (xx)
DK (1)	DK1689751T3 (xx)
EA (1)	EA011772B1 (xx)
EC (1)	ECSP066580A (xx)
ES (1)	ES2351622T3 (xx)
GB (1)	GB0327319D0 (xx)
GE (1)	GEP20084528B (xx)
HK (2)	HK1099286A1 (xx)
HR (1)	HRP20100651T1 (xx)
IL (1)	IL175433A (xx)
IS (1)	IS8406A (xx)
MA (1)	MA28172A1 (xx)
ME (1)	ME01216B (xx)
MX (1)	MXPA06005914A (xx)
MY (1)	MY140872A (xx)
NL (1)	NL1027568C2 (xx)
NO (1)	NO336526B1 (xx)
NZ (1)	NZ548097A (xx)
OA (1)	OA13289A (xx)
PA (1)	PA8617701A1 (xx)
PE (1)	PE20051061A1 (xx)
PL (1)	PL1689751T3 (xx)
PT (1)	PT1689751E (xx)
RS (1)	RS51556B (xx)
SG (1)	SG133614A1 (xx)
SI (1)	SI1689751T1 (xx)
TN (1)	TNSN06154A1 (xx)
TW (1)	TWI265031B (xx)
UA (1)	UA81994C2 (xx)
UY (1)	UY28625A1 (xx)
WO (1)	WO2005049616A1 (xx)
ZA (1)	ZA200602899B (xx)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2580857A1 (en)	2004-09-20	2006-09-28	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286648A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AU2005286731A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
WO2006034440A2 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006034315A2 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
CA2580762A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as therapeutic agents
AU2005286728A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
WO2006046135A2 (en) *	2004-10-28	2006-05-04	Pharmacia & Upjohn Company Llc	Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors
ATE493413T1 (de) *	2005-05-12	2011-01-15	Pfizer	Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-
WO2007130075A1 (en)	2005-06-03	2007-11-15	Xenon Pharmaceuticals Inc.	Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
NL1029244C2 (nl) *	2005-06-10	2006-12-12	Ronald Silfried Marlin	Middel ter vergroting van het mannelijk geslachtsorgaan.
DE102005050377A1 (de) *	2005-10-21	2007-04-26	Bayer Healthcare Ag	Heterocyclische Verbindungen und ihre Verwendung
NL2000291C2 (nl) *	2005-11-10	2009-02-17	Pfizer Prod Inc	1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
US7601713B2 (en)	2005-12-15	2009-10-13	Rigel Pharmaceuticals, Inc.	Kinase inhibitors and their uses
EP1820502A1 (en) *	2006-02-10	2007-08-22	Laboratorios Del Dr. Esteve, S.A.	Active substance combination comprising azolylcarbinol compounds
WO2007113243A2 (en) *	2006-03-31	2007-10-11	Investigación Y Clínica Andrológicas S.L.	Use of pde 5 inhibitors for the treatment of overactive bladder
WO2008132589A1 (en) *	2007-05-01	2008-11-06	Pfizer Limited	Combinations comprising pregabalin
WO2009050554A2 (en) *	2007-10-19	2009-04-23	Pfizer Inc.	Treatment of central nervous system disorders
DE102008063992A1 (de) *	2008-12-19	2010-09-02	Lerner, Zinoviy, Dipl.-Ing.	Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
WO2012131539A1 (en)	2011-03-31	2012-10-04	Pfizer Inc.	Novel bicyclic pyridinones
WO2012172449A1 (en)	2011-06-13	2012-12-20	Pfizer Inc.	Lactams as beta secretase inhibitors
JP6043355B2 (ja)	2011-08-31	2016-12-14	ファイザー・インク	ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
ES2585262T3 (es)	2012-05-04	2016-10-04	Pfizer Inc	Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
US9260455B2 (en)	2012-09-20	2016-02-16	Pfizer Inc.	Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
EP2931731A1 (en)	2012-12-11	2015-10-21	Pfizer Inc.	Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en)	2012-12-19	2016-08-02	Pfizer Inc.	Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
JP2016507551A (ja)	2013-02-13	2016-03-10	ファイザー・インク	ヘテロアリール置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
BR112015019276A2 (pt)	2013-02-19	2017-07-18	Pfizer	compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
WO2015049616A1 (en)	2013-10-04	2015-04-09	Pfizer Inc.	Novel bicyclic pyridinones as gamma-secretase modulators
WO2015091428A1 (en) *	2013-12-20	2015-06-25	Bayer Pharma Aktiengesellschaft	Glucose transport inhibitors
DK3126361T3 (da)	2014-04-01	2020-01-02	Pfizer	Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer
JP6554116B2 (ja) *	2014-04-04	2019-07-31	ハー・ルンドベック・アクチエゼルスカベット	Ｐｄｅ１阻害剤としてのハロゲン化キナゾリン−ｔｈｆ−アミン
AP2016009493A0 (en)	2014-04-10	2016-10-31	Pfizer	2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
US10131669B2 (en)	2014-07-24	2018-11-20	Pfizer Inc.	Pyrazolopyrimidine compounds
MX376283B (es)	2014-08-06	2025-03-07	Pfizer	Compuestos de imidazopiridazina.
CN107001377B (zh) *	2014-12-08	2019-09-10	爱尔兰詹森科学公司	对呼吸道合胞病毒(rsv)的复制具有抑制活性的哌啶取代的吡唑并[1,5-a]嘧啶衍生物
CN107406445B (zh)	2015-02-03	2019-12-24	辉瑞公司	新颖环丙苯并呋喃基吡啶并吡嗪二酮类
US11472805B2 (en)	2015-06-17	2022-10-18	Pfizer, Inc.	Tricyclic compounds and their use as phosphodiesterase inhibitors
WO2017051303A1 (en)	2015-09-24	2017-03-30	Pfizer Inc.	Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
EP3353183A1 (en)	2015-09-24	2018-08-01	Pfizer Inc	N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3]thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl]amides
WO2017051294A1 (en)	2015-09-24	2017-03-30	Pfizer Inc.	N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
AU2017223132B2 (en)	2016-02-23	2019-12-05	Pfizer Inc.	6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
BR112018077257A2 (pt)	2016-07-01	2019-04-02	Pfizer Inc.	derivados de 5,7-di-hidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas
PL3642202T3 (pl)	2017-06-22	2023-03-13	Pfizer Inc.	Pochodne dihydropirolopirydyny
CN112154145B (zh)	2018-03-23	2023-10-17	辉瑞大药厂	哌嗪氮杂螺衍生物
WO2019233994A1 (en)	2018-06-04	2019-12-12	Exscientia Ltd	Pyrazolopyrimidine compounds as adenosine receptor antagonists
JP7579253B2 (ja) *	2018-08-24	2024-11-07	ターンズ・インコーポレイテッド	甲状腺ホルモン受容体ベータアゴニスト化合物
WO2022182658A1 (en)	2021-02-23	2022-09-01	Hoth Therapeutics, Inc.	Use of aprepitant for treating alzheimer's disease
WO2024118524A1 (en)	2022-11-28	2024-06-06	Cerevel Therapeutics, Llc	Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW444018B (en) *	1992-12-17	2001-07-01	Pfizer	Pyrazolopyrimidines
GB9823102D0 (en) *	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
DE69911448T2 (de) *	1998-10-23	2004-04-08	Pfizer Inc.	Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
DE10031236A1 (de) *	2000-06-27	2002-01-10	Qiagen Gmbh	Verwendung von Carbonsäuren und anderen Additiven in Kombination mit kationischen Verbindungen zur Stabilisierung von Nukleinsäuren in biologischen Materialien
DE10031584A1 (de) *	2000-06-29	2002-01-10	Merck Patent Gmbh	5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
EP1348707B1 (en) *	2002-03-28	2010-08-25	Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO)	Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
WO2004096810A1 (en) *	2003-04-29	2004-11-11	Pfizer Limited	5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension

2003
- 2003-11-24 GB GBGB0327319.0A patent/GB0327319D0/en not_active Ceased
2004
- 2004-11-12 AP AP2006003591A patent/AP2227A/xx active
- 2004-11-12 AT AT04798876T patent/ATE485297T1/de active
- 2004-11-12 GE GEAP20049412A patent/GEP20084528B/en unknown
- 2004-11-12 RS RSP-2010/0534A patent/RS51556B/en unknown
- 2004-11-12 BR BRPI0416869-0A patent/BRPI0416869A/pt not_active Application Discontinuation
- 2004-11-12 MX MXPA06005914A patent/MXPA06005914A/es active IP Right Grant
- 2004-11-12 SI SI200431562T patent/SI1689751T1/sl unknown
- 2004-11-12 SG SG200704860-6A patent/SG133614A1/en unknown
- 2004-11-12 CN CN2008100859397A patent/CN101362764B/zh not_active Expired - Fee Related
- 2004-11-12 CN CN200810085940XA patent/CN101362765B/zh not_active Expired - Fee Related
- 2004-11-12 CN CN200910151866A patent/CN101647802A/zh active Pending
- 2004-11-12 KR KR1020067010152A patent/KR100848216B1/ko not_active Expired - Fee Related
- 2004-11-12 WO PCT/IB2004/003747 patent/WO2005049616A1/en active Application Filing
- 2004-11-12 ES ES04798876T patent/ES2351622T3/es not_active Expired - Lifetime
- 2004-11-12 KR KR1020087009034A patent/KR100893999B1/ko not_active Expired - Fee Related
- 2004-11-12 AU AU2004290643A patent/AU2004290643B2/en not_active Ceased
- 2004-11-12 NZ NZ548097A patent/NZ548097A/en not_active IP Right Cessation
- 2004-11-12 CN CN2004800345707A patent/CN1882591B/zh not_active Expired - Fee Related
- 2004-11-12 ME MEP-2010-203A patent/ME01216B/me unknown
- 2004-11-12 EP EP04798876A patent/EP1689751B1/en not_active Expired - Lifetime
- 2004-11-12 CA CA002546987A patent/CA2546987C/en not_active Expired - Fee Related
- 2004-11-12 JP JP2006540647A patent/JP4056015B2/ja not_active Expired - Fee Related
- 2004-11-12 DK DK04798876.1T patent/DK1689751T3/da active
- 2004-11-12 PL PL04798876T patent/PL1689751T3/pl unknown
- 2004-11-12 DE DE602004029705T patent/DE602004029705D1/de not_active Expired - Lifetime
- 2004-11-12 EA EA200600677A patent/EA011772B1/ru not_active IP Right Cessation
- 2004-11-12 OA OA1200600166A patent/OA13289A/en unknown
- 2004-11-12 PT PT04798876T patent/PT1689751E/pt unknown
- 2004-11-22 UY UY28625A patent/UY28625A1/es active IP Right Grant
- 2004-11-22 MY MYPI20044834A patent/MY140872A/en unknown
- 2004-11-22 PE PE2004001138A patent/PE20051061A1/es not_active Application Discontinuation
- 2004-11-23 NL NL1027568A patent/NL1027568C2/nl not_active IP Right Cessation
- 2004-11-23 PA PA20048617701A patent/PA8617701A1/es unknown
- 2004-11-23 TW TW093136019A patent/TWI265031B/zh not_active IP Right Cessation
- 2004-11-23 AR ARP040104331A patent/AR046711A1/es not_active Application Discontinuation
- 2004-12-11 UA UAA200605669A patent/UA81994C2/uk unknown
2006
- 2006-04-10 IS IS8406A patent/IS8406A/is unknown
- 2006-04-10 ZA ZA200602899A patent/ZA200602899B/en unknown
- 2006-05-04 IL IL175433A patent/IL175433A/en not_active IP Right Cessation
- 2006-05-23 EC EC2006006580A patent/ECSP066580A/es unknown
- 2006-05-23 CR CR8416A patent/CR8416A/es unknown
- 2006-05-24 TN TNP2006000154A patent/TNSN06154A1/fr unknown
- 2006-05-24 MA MA29050A patent/MA28172A1/fr unknown
- 2006-06-23 NO NO20062950A patent/NO336526B1/no not_active IP Right Cessation
2007
- 2007-05-22 HK HK07105414.0A patent/HK1099286A1/xx not_active IP Right Cessation
2009
- 2009-08-03 HK HK09107080.7A patent/HK1128917A1/xx not_active IP Right Cessation
2010
- 2010-11-24 CY CY20101101062T patent/CY1110933T1/el unknown
- 2010-11-26 HR HR20100651T patent/HRP20100651T1/hr unknown

Also Published As

Publication number	Publication date
NO336526B1 (no)	2015-09-21
EP1689751A1 (en)	2006-08-16
AU2004290643A1 (en)	2005-06-02
CN1882591A (zh)	2006-12-20
CN101362764B (zh)	2011-04-20
NL1027568C2 (nl)	2005-11-30
UY28625A1 (es)	2005-06-30
HK1128917A1 (en)	2009-11-13
TW200520758A (en)	2005-07-01
WO2005049616A1 (en)	2005-06-02
MY140872A (en)	2010-01-29
EP1689751B1 (en)	2010-10-20
ATE485297T1 (de)	2010-11-15
HK1099286A1 (en)	2007-08-10
CR8416A (es)	2006-11-15
MA28172A1 (fr)	2006-09-01
PA8617701A1 (es)	2005-08-04
NL1027568A1 (nl)	2005-05-26
CN101362765B (zh)	2011-02-02
TWI265031B (en)	2006-11-01
KR20070026334A (ko)	2007-03-08
BRPI0416869A (pt)	2007-03-27
RS51556B (en)	2011-06-30
TNSN06154A1 (fr)	2007-11-15
PL1689751T3 (pl)	2011-03-31
NZ548097A (en)	2008-12-24
KR20080052666A (ko)	2008-06-11
AP2006003591A0 (en)	2006-04-30
JP2007512314A (ja)	2007-05-17
ME01216B (me)	2013-03-20
CN101647802A (zh)	2010-02-17
EA011772B1 (ru)	2009-06-30
IL175433A (en)	2011-08-31
GB0327319D0 (en)	2003-12-24
IL175433A0 (en)	2006-09-05
AU2004290643B2 (en)	2008-08-07
DK1689751T3 (da)	2011-01-17
HRP20100651T1 (hr)	2011-01-31
NO20062950L (no)	2006-08-23
KR100848216B1 (ko)	2008-07-24
UA81994C2 (xx)	2008-02-25
SG133614A1 (en)	2007-07-30
CA2546987A1 (en)	2005-06-02
CN1882591B (zh)	2011-08-10
ECSP066580A (es)	2006-12-20
AR046711A1 (es)	2005-12-21
CA2546987C (en)	2009-05-12
JP4056015B2 (ja)	2008-03-05
CY1110933T1 (el)	2015-06-10
CN101362764A (zh)	2009-02-11
OA13289A (en)	2007-01-31
IS8406A (is)	2006-04-10
DE602004029705D1 (de)	2010-12-02
EA200600677A1 (ru)	2006-12-29
MXPA06005914A (es)	2006-06-27
SI1689751T1 (sl)	2011-01-31
AP2227A (en)	2011-03-29
CN101362765A (zh)	2009-02-11
ES2351622T3 (es)	2011-02-08
PT1689751E (pt)	2010-11-29
PE20051061A1 (es)	2005-12-12
WO2005049616A8 (en)	2006-06-01
KR100893999B1 (ko)	2009-04-20
GEP20084528B (en)	2008-11-10

Publication	Publication Date	Title
ZA200602899B (en)	2007-07-25	5,7-Diaminopyrazolo [4,3-d] Pyrimidlnes with PDE-5 Inhibiting Activity
EP2575473B1 (en)	2016-01-20	Soluble guanylate cyclase activators
JP6251183B2 (ja)	2017-12-20	置換された縮合ピリミジンおよびトリアジン化合物ならびにその使用
EP2373317B1 (en)	2016-12-14	4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
US9611278B2 (en)	2017-04-04	Soluble guanylate cyclase activators
WO2015088886A1 (en)	2015-06-18	Soluble guanylate cyclase activators
MX2014000029A (es)	2014-02-17	Pirazolopiridinas sustituidas con heteroarilo y uso de las mismas como estimuladores de guanilato ciclasas solubles.
US7572799B2 (en)	2009-08-11	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1689752B1 (en)	2008-02-27	Pyrazolopyrimidines
WO2009050554A2 (en)	2009-04-23	Treatment of central nervous system disorders
ZA200506975B (en)	2006-12-27	5,7-diaminopyrazolo'4,3-D! pyrimidines useful in the treatment of hypertension